Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug;48(3):705-724.
doi: 10.1016/j.rdc.2022.03.006. Epub 2022 Jul 5.

Treatment Guidelines in Vasculitis

Affiliations
Review

Treatment Guidelines in Vasculitis

Tanaz A Kermani et al. Rheum Dis Clin North Am. 2022 Aug.

Abstract

The vasculitides encompass a group of inflammatory conditions affecting the blood vessels with severe consequences including tissue ischemia, structural abnormalities, such as aneurysms/dissections, and end organ damage. The different forms are commonly classified based on the size of the blood vessel involved as large-vessel, medium-vessel, and small-vessel vasculitis. The American College of Rheumatology/Vasculitis Foundation recently published guidelines on the management of several forms of primary systemic vasculitides. In this review, the recommendations for giant cell arteritis, Takayasu arteritis, polyarteritis nodosa, granulomatosis with polyangiitis, microscopic polyangiitis, and eosinophilic granulomatosis with polyangiitis are discussed. We highlight the key recommendations, aspects where they diverge from other published guidelines, controversies, and areas of uncertainty.

Keywords: Eosinophilic granulomatosis with polyangiitis; Giant cell arteritis; Granulomatosis with polyangiitis; Microscopic polyangiitis; Polyarteritis nodosa; Takayasu arteritis; Treatment Guidelines; Vasculitis.

PubMed Disclaimer

Conflict of interest statement

Disclosure Dr T.A. Kermani has nothing to disclose. Dr K.J. Warrington has received clinical trial support from Kiniksa and Eli Lilly & Co; honoraria from Chemocentryx. Dr A.B. Dua has received honoraria from Chemocentryx, Novartis, and Abbvie.

MeSH terms